

# 6<sup>th</sup> ESDO MASTERCLASS

## Multidisciplinary Challenges in GI Cancers



November 18 - 19, 2022

Brussels, Belgium

**Register and Join us**

**Venue: KBR - Royal Library of Belgium, 1000 Brussels, Kunstberg 28 [www.kbr.be](http://www.kbr.be)**

Internationally renowned experts with multidisciplinary views will discuss and integrate the latest data in gastrointestinal oncology, engaging in debates about novel challenges and anticipating new perspectives in the treatment and rapidly evolving therapeutic management of digestive cancers. The Masterclass is held in a small-size face-to-face format over 2 days with interactive discussions, pro/contra debates and case presentations, including a social evening programme. Organisers are **European Society of Digestive Oncology** and **Belgian Group of Digestive Oncology**.

### The Organising Committee:

**Prof. Eric Van Cutsem**  
ESDO President

**Prof. Alain Hendlisz**  
BGDO President

**Prof. Jean-Luc Van Laethem**  
Scientific Committee Chair

### The Scientific Committee:

#### ESDO

Thomas Gruenberger, Austria  
Tamara Matysiak-Budnik, France  
Thomas Seufferlein, Germany  
Eric Van Cutsem, Belgium  
Jean-Luc Van Laethem, Belgium

#### BGDO

Ivan Borbath, Belgium  
Saskia Carton, Belgium  
Karen Geboes, Belgium  
Alain Hendlisz, Belgium  
Timon Vandamme, Belgium

#### ESDO Young Group

Alica Beutel, Germany  
Ana-Maria Bucalau, Belgium  
Pieter-Jan Cuyle, Belgium  
Michela Guardascione, Italy

#### Organisation:

Liz Tanzer  
tel. +43 1405 1383 38  
[masterclass@esdo.eu](mailto:masterclass@esdo.eu)  
**ESDO** c/o WMA GmbH  
1090 Vienna, Alser Strasse 4  
[www.esdo.eu](http://www.esdo.eu)

#### Onsite Organisation & Registration:

Anne-Sophie Wirtz  
tel. + 32 476 312 411  
[management@bgdo.org](mailto:management@bgdo.org)  
**BGDO** 1930 Zaventem  
Leuvensesteenweg 643 b 8  
[www.bgdo.org](http://www.bgdo.org)



# Multidisciplinary challenges in GI cancers

---

Friday 18 November 2022 9h – 18h

## **Part 1: Oncosurgical challenges for localised upper GI cancer**

9h00 Welcome

### **Localised esophagogastric/GE junction cancers: more or less chemoRT?**

**Moderators: Tamara Matysiak (Nantes) and Philippe Naftoux (Leuven)**

9h10 Case: voting and discussion Ana-Maria Bucalau (Brussels)

9h20 Systemic therapy is the golden bullet to approach localised OG/GEJ tumours (including chemo +/- IO) Markus Möhler (Mainz)

9h35 Chemoradiation may be the standard to approach localised OG/GEJ tumours in EG cancers Violaine Randrian (Poitiers)

9h50 Discussion

### **Localised pancreatic adenocarcinoma: more or less (neo)adjuvant therapy?**

**Moderators: Thomas Gruenberger (Vienna) and Jean-Luc Van Laethem (Brussels)**

10h00 Case: voting and discussion Elisabeth Stragier (Hasselt)

10h10 We should shift to neo-adjuvant therapy for all PDAC patients (including RT) Thomas Seufferlein (Ulm)

10h25 Upfront surgery followed by adjuvant treatment is still a valid option Bas Groot Koerkamp (Rotterdam)

10h40 Discussion

**10h50 Coffee Break**

### **Borderline resectable biliary tract cancer: more neoadjuvant therapy?**

**Moderators: Ivan Borbath (Brussels) and Filip Gryspeerdt (Ghent)**

11h20 Case: voting and discussion Violaine Randrian (Poitiers)

11h30 Neo-adjuvant therapy offers many opportunities for borderline resectable BTC (chemo? IO? SIRT?) Anne Demols (Brussels)

11h45 Borderline resectable BTC should be tackled primarily by surgical techniques Thomas Gruenberger (Vienna)

12h00 Discussion

### **BCLC stage B hepatocellular carcinoma: more or less locoregional therapy?**

**Moderator: Ivan Borbath (Brussels)**

12h10 Case: voting and discussion Gontran Verset (Brussels)

12h20 Locoregional therapy remains the standard for BCLC stage B. Jens Ricke (Munich)

12h35 Systemic therapy is a good option in HCC BCLC stage B. Jeroen Dekervel (Leuven)

12h50 Discussion

**13h Lunch Break**

# Multidisciplinary challenges in GI cancers

---

## **Part 2: Personalised approaches for pushing the boundaries in GI oncology**

14h00 Welcome

### **CRC stage II(III): more ctDNA, less clinicopathological prognostication?**

**Moderators: Eric Van Cutsem (Leuven) and Marc Van Den Eynde (Louvain)**

14h10 Case: voting and discussion Pieter-Jan Cuyle (Bonheiden)

14h20 ctDNA is the most reliable biomarker to drive  
CRC stage II/III decision making Timon Vandamme (Antwerp)

14h35 Clinicopathological factors including immune infiltrates  
should drive stage II/III decision making Jean-François Emile (Paris)

14h50 Discussion

### **Rectal cancer: more TNT, less surgery?**

**Moderators: Marc Peeters (Antwerp) and Albert Wolthuis (Leuven)**

15h00 Case: voting and discussion Zineb Benbrahim (Fez)

15h10 A radiation oncologist's view on organ sparing  
strategies in rectal cancer Philippe Martinive (Brussels)

15h25 An oncologist's view on organ sparing  
strategies in rectal cancer Geke Hospers (Groningen)

15h40 Discussion

**15h50 Coffee Break**

### **Liver-limited CRC metastases: more or less perioperative chemotherapy?**

**Moderators: Alain Hendlisz (Brussels) and Eric Van Cutsem (Leuven)**

16h20 Liver-limited mCRC case: voting and discussion Hossein Taghizadeh (St. Pölten)

16h30 We should go for downstaging and  
resection/ablation therapy in all patients Thomas Gruenberger (Vienna)

16h45 We should only select good candidates for this strategy  
Vincent Donckier (Brussels)

17h00 Discussion

### **Oligometastatic non-CRC GI malignancies: more locoregional approaches or just systemic therapy?**

**Moderators: Karen Geboes (Ghent) and Jean-Luc Van Laethem (Brussels)**

17h10 Case: voting and discussion Yawen Dong (Vienna)

17h20 We should implement more surgical/locoregional  
approaches in oligometastatic GI cancer Michela Guardascione (Aviano)

17h35 We should stick to systemic therapy for systemic diseases Lucjan Wyrwicz (Warsaw)

17h50 Discussion

**18h End of Day 1**

# Multidisciplinary challenges in GI cancers

---

Saturday 19 November 2022 9h – 12h

## **PART 3 Precision medicine ready for daily practice?**

9h00 Welcome

### **Microsatellite instable Colorectal cancers: less or even no surgery needed?**

**Moderators: Geerard Beets (Amsterdam) and Pieter-Jan Cuyle (Bonheiden)**

9h10 Case: voting and discussion Laura Mans (Brussels)

9h20 Do we need surgery in MSI-high colorectal cancer? Geerard Beets (Amsterdam)

9h35 Do we need surgery in MSI-high non-colorectal cancer? Karen Geboes (Ghent)

9h50 Discussion

### **Precision medicine in advanced GI cancer**

**Moderator: Karen Geboes (Ghent) and Eric Van Cutsem (Leuven)**

10h00 Case: voting and discussion Piotr Wysocki (Warsaw)

10h10 When and how to implement precision medicine in advanced colorectal cancer? Sabine Tejpar (Leuven)

10h25 When and how to implement precision medicine in advanced non-colorectal cancer? Lukas Perkhofer (Ulm)

10h40 Discussion

**10h50 Coffee Break**

### **Tumour response evaluation: more metabolic, less morphologic?**

**Moderators: Alain Hendlisz (Brussels) and Timon Vandamme (Antwerp)**

11h10 - pro metabolic Sigrid Stroobants (Antwerp)

11h25 - pro morphologic Maria Antonietta Bali (Brussels)

### **Molecular imaging in GI oncology:**

**Moderator: Thomas Seufferlein (Ulm)**

11h40 Current indications and theranostic perspectives Ambros Beer (Ulm)

12h00 Discussion

**12h30 End of Programme**

# Multidisciplinary challenges in GI cancers

---

## The Faculty:

Prof. Maria Antonietta Bali  
University Hospital Brussels,  
Belgium

Prof. Ambros Beer  
University Clinic Ulm,  
Germany

Prof. Geerard Beets  
NCI Amsterdam, Netherlands

Dr. Zineb Benbrahim  
University Hospital Fès,  
Morocco

Prof. Ivan Borbath  
University Hospital Brussels,  
Belgium

Dr. Ana-Maria Bucalau  
University Hospital Brussels,  
Belgium

Dr. Pieter-Jan Cuyle  
Imelda General Hospital,  
Bonheiden, Belgium

Prof. Jeroen Dekervel  
University Hospital Leuven,  
Belgium

Prof. Anne Demols  
University Hospital Brussels,  
Belgium

Prof. Vincent Donckier  
University Hospital Brussels,  
Belgium

Dr. Yawen Dong  
Clinic Favoriten, Vienna,  
Austria

Prof. Jean-François Emile  
University Hospital  
Versailles, France

Prof. Karen Geboes  
University Hospital Ghent,  
Belgium

Prof. Bas Groot Koerkamp  
Erasmus University Hospital  
Rotterdam, Netherlands

Prof. Thomas Gruenberger  
Clinic Favoriten, Vienna,  
Austria

Dr. Filip Gryspeerdt  
University Hospital Ghent,  
Belgium

Dr. Michela Guardascione  
National Cancer Institute  
Aviano, Italy

Prof. Alain Hendlisz  
University Hospital Brussels,  
Belgium

Prof. Geke Hoppers  
University Hospital  
Groningen, Netherlands

Dr. Laura Mans  
University Hospital Brussels,  
Belgium

Dr. Philippe Martinive  
University Hospital Brussels,  
Belgium

Prof. Tamara Matysiak  
University Hospital Nantes,  
France

Prof. Markus Möhler  
University Clinic Mainz,  
Germany

Prof. Philippe Nafteux  
University Hospital Leuven,  
Belgium

Prof. Marc Peeters  
University Hospital Antwerp,  
Belgium

Dr. Lukas Perkhofer  
University Clinic Ulm,  
Germany

Dr. Violaine Randrian  
University Hospital Poitiers,  
France

Prof. Jens Ricke  
University Clinic Munich,  
Germany

Prof. Thomas Seufferlein  
University Clinic Ulm,  
Germany

Dr. Elisabeth Stragier  
Jessa Hospital Hasselt,  
Belgium

Prof. Sigrid Stroobants  
University Hospital Antwerp,  
Belgium

Dr. Hossein Taghizadeh  
University Clinic St. Pölten,  
Austria

Prof. Sabine Tejpar  
University Hospital Leuven,  
Belgium

Prof. Eric Van Cutsem  
University Hospital Leuven,  
Belgium

Prof. Marc Van den Eynde  
University Hospital Louvain,  
Belgium

Prof. Jean-Luc Van Laethem  
University Hospital Brussels,  
Belgium

Dr. Timon Vandamme  
University Hospital Antwerp,  
Belgium

Dr. Gontran Verset  
University Hospital Brussels,  
Belgium

Prof. Albert Wolthuis  
University Hospital Leuven,  
Belgium

Prof. Lucjan Wyrwicz  
National Research Institute  
of Oncology, Warsaw, Poland

Dr. Piotr Wysocki  
Medical University Warsaw,  
Poland